French drug price cuts loom in €10bn savings plan
This article was originally published in Scrip
Executive Summary
The French pharmaceutical industry is again under the hammer after the parliament passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period, €3.5bn of which will affect medicines, and probably medical devices, in the form of selected price cuts, together with moves to increase the market share of generics.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.